FUSILEV(TM) is indicated after high-dose methotrexate therapy in patients with osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists.
Registration acknowledges the Terms and Conditions and Privacy Policy
Enter your MM&M registration email address to receive a password reset link.
It looks like we already have a MM&M account for:
Please confirm the information BELOW to link this account to your account
By registering you agree with our Terms and Conditions and Privacy Policy.
« CANCEL AND GO BACKNot you? Create an account for free »
Please confirm the information BELOW before Signing In
By registering you agree with our Terms and Conditions and Privacy Policy.
« CANCEL AND GO BACK